Milk Thistle and Chemo: Questions Continue

The medicinal herb milk thistle may reduce the liver inflammation often caused by chemotherapy, researchers say.

A recent study, reported in the December 14 online edition of the journal Cancer, examined how the herb affected liver inflammation over a 28 day period in 50 children undergoing chemotherapy for acute lymphoblastic leukemia, HealthDay News reports.

Compared to a placebo group, the patients who received milk thistle had significantly lower levels of the enzymes AST and ALT, indicating a reduced impact on the liver, according Dr Kara Kelly, the study's lead researcher from Columbia University Medical Center's Herbert Irving Comprehensive Cancer Center.

"If these results are confirmed, milk thistle may allow us to treat liver inflammation or prevent it from occurring, which will allow better delivery of chemotherapy drugs," she told the news source.

Aside from reducing a harmful side effect of the cancer treatment, the herb seemed to help the study's participants tolerate higher doses of chemotherapy as well. 61 percent of the children who received milk thistle needed dose reductions, compared to 72 percent of the control group.

However, the National Cancer Institute has an informational page on milk thistle that is cautious at best, saying “there are no published clinical trials of milk thistle in patients with cancer. Two published case reports describe the use of milk thistle as either a treatment or an adjunctive therapy in individuals with cancer.”

More information:
http://www.cancer.gov/cancertopics/pdq/cam/milkthistle/HealthProfessiona...

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap